Moberg Pharma´s Interim report January - September 2023
MOB-015 HAS RECEIVED NATIONAL APPROVALS IN 10 EU COUNTRIES, ANOTHER 3 APPROVALS ARE EXPECTEDNINE-MONTH PERIOD (JAN-SEP 2023) · EBITDA SEK -17.4 million (-13.7) · Operating profit (EBIT) SEK -19.2 million (-15.6) · Profit after tax SEK -14.6 million (-12.6) · Total profit SEK -14.6 million (-12.6) · Diluted earnings per share SEK -1.24 (-1.84) · Cash and cash equivalents amounted to SEK 101.5 million (142.5) THIRD QUARTER (JUL-SEP 2023) · EBITDA SEK -6.6 million (-4.6) · Operating profit (EBIT) SEK -7.3 million (-5.3) · Profit after tax SEK -5.8 million (-4.